BNGO
Bionano Genomics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$1.20
−3.23%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 30.2M | 28.5M | 30.8M | 36.1M | 27.8M |
| Cost of Revenue | 15.8M | 22.3M | 30.4M | 26.6M | 21.9M |
| Gross Profit | 14.3M | 6.3M | 380.0K | 9.6M | 5.9M |
| Operating Expenses | |||||
| R&D Expense | 12.2M | 11.4M | 24.8M | 54.0M | 49.0M |
| SG&A Expense | 34.3M | 28.2M | 51.9M | 95.0M | 88.6M |
| General & Admin Expense | 8.5M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 27.7M | 75.8M | — |
| Total Operating Expenses | 46.5M | 39.6M | 104.4M | 224.8M | 137.6M |
| Cost and Expenses | 62.4M | 61.8M | 134.8M | 251.4M | 159.5M |
| Operating Income (EBIT) | (32.2M) | (33.3M) | (104.0M) | (215.2M) | (131.7M) |
| Non-Operating | |||||
| Interest Income | 913.0K | 1.1M | 2.1M | 3.3M | 1.5M |
| Interest Expense | 213.0K | 298.0K | 289.0K | 5.1M | 298.0K |
| Net Interest Income | 700.0K | 813.0K | 1.8M | (1.8M) | 1.2M |
| Other Non-Op Income/Expense | 93.0K | 7.0M | (8.0M) | (17.2M) | 986.0K |
| Non-Operating Income (excl Interest) | (306.0K) | (7.3M) | 7.7M | 12.1M | (1.3M) |
| EBT (Pre-Tax Income) | (32.1M) | (26.3M) | (112.0M) | (232.4M) | (130.7M) |
| Income Tax Expense | 66.0K | 67.0K | 33.0K | 62.0K | 1.9M |
| Bottom Line | |||||
| Net Income | (32.2M) | (26.4M) | (112.0M) | (232.5M) | (132.6M) |
| Earnings from Cont. Ops | (32.2M) | (26.4M) | (112.0M) | (232.5M) | (132.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (32.2M) | (26.4M) | (112.0M) | (232.5M) | (132.6M) |
| Per Share | |||||
| Basic EPS | ($3.73) | ($4.85) | ($88.13) | ($408.48) | ($275.09) |
| Diluted EPS | ($3.73) | ($4.85) | ($88.13) | ($408.48) | ($275.09) |
| Revenue Per Share | $2.61 | $5.24 | $24.21 | $63.45 | $57.68 |
| Shares | |||||
| Basic Shares Outstanding | 11.5M | 5.4M | 1.3M | 569166 | 482016 |
| Diluted Shares Outstanding | 11.5M | 5.4M | 1.3M | 569166 | 482016 |
| Profitability Metrics | |||||
| EBITDA | (22.4M) | (16.3M) | (97.5M) | (213.6M) | (120.3M) |
| D&A | 9.5M | 9.7M | 14.2M | 13.7M | 10.1M |
| EBIT | (31.9M) | (26.0M) | (111.7M) | (227.3M) | (130.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026